Skip to main content
Erschienen in: Strahlentherapie und Onkologie 10/2014

01.10.2014 | Original article

Protection of quality and innovation in radiation oncology

The prospective multicenter trial QUIRO of DEGRO: evaluation of time, attendance of medical staff, and resources during radiotherapy with tomotherapy

verfasst von: Dr. Cornelia Winkler, Dr. M. N. Duma, Dr. W. Popp, Prof. H. Sack, Prof. V. Budach, Prof. M. Molls, S. Kampfer

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The technical progress in radiotherapy in recent years has been tremendous. This also implies a change of human and time resources. However, there is a lack of data on this topic. Therefore, the DEGRO initiated several studies in the QUIRO project on this subject. The present publication focuses on results for tomotherapy systems and compares them with other IMRT techniques.

Methods

Over a period of several months, time allocation was documented using a standard form at two university hospitals. The required time for individual steps in the treatment planning process was recorded for all involved professional groups (physicist, technician, and physician) by themselves. The time monitoring at the treatment machines was performed by auxiliary employees (student research assistants). Evaluation of the data was performed for all recorded data as well as by tumor site. A comparison was made between the two involved institutions.

Results

A total of 1,691 records were analyzed: 148 from head and neck (H&N) tumors, 460 from prostate cancer, 136 from breast cancer, and 947 from other tumor entities. The mean value of all data from both centers for the definition of the target volumes for H&N tumors took a radiation oncology specialist 75 min, while a physicist needed for the physical treatment planning 214 min. For prostate carcinomas, the times were 60 and 147 min, respectively, and for the group of other entities 63 and 192 min, respectively. For the first radiation treatment, the occupancy time of the linear accelerator room was 31, 26, and 30 min for each entity (H&N, prostate, other entities, respectively). For routine treatments 22, 18, and 21 min were needed for the particular entities. Major differences in the time required for the individual steps were observed between the two centers.

Conclusion

This study gives an overview of the time and personnel requirements in radiation therapy using a tomotherapy system. The most representative analysis could be done for the room occupancy times during treatment in both centers. Due to the partly small amount of data and differing planning workflows between the two centers, it is problematic to draw a firm conclusion with regard to planning times. Overall, the time required for the tomotherapy treatment and planning is slightly higher compared to other IMRT techniques.
Literatur
1.
Zurück zum Zitat Budach W, Bölke E, Fietkau R et al (2011) Evaluation of time, attendance of medical staff, and resources during radiotherapy for head and neck cancer patients: the DEGRO-QUIRO trial. Strahlenther Onkol 187:449–460PubMedCrossRef Budach W, Bölke E, Fietkau R et al (2011) Evaluation of time, attendance of medical staff, and resources during radiotherapy for head and neck cancer patients: the DEGRO-QUIRO trial. Strahlenther Onkol 187:449–460PubMedCrossRef
2.
Zurück zum Zitat Blank E, Willich N, Fietkau R et al (2012) Evaluation of time, attendance of medical staff, and resources during radiotherapy for breast cancer patients. The DEGRO-QUIRO trial. Strahlenther Onkol 188:113–119PubMedCrossRef Blank E, Willich N, Fietkau R et al (2012) Evaluation of time, attendance of medical staff, and resources during radiotherapy for breast cancer patients. The DEGRO-QUIRO trial. Strahlenther Onkol 188:113–119PubMedCrossRef
3.
Zurück zum Zitat Fietkau R, Budach W, Zamboglou N et al (2012) Time management in radiation oncology: development and evaluation of a modular system based on the example of rectal cancer treatment. The DEGRO—QUIRO trial. Strahlenther Onkol 188:5–11PubMedCrossRef Fietkau R, Budach W, Zamboglou N et al (2012) Time management in radiation oncology: development and evaluation of a modular system based on the example of rectal cancer treatment. The DEGRO—QUIRO trial. Strahlenther Onkol 188:5–11PubMedCrossRef
4.
Zurück zum Zitat Zabel-du Bois A, Milker-Zabel S, Henzel M et al (2012) Evaluation of time, attendance of medical staff, and resources during stereotactic radiotherapy/radiosurgery: QUIRO-DEGRO Trial. Strahlenther Onkol 188:769–776PubMedCrossRef Zabel-du Bois A, Milker-Zabel S, Henzel M et al (2012) Evaluation of time, attendance of medical staff, and resources during stereotactic radiotherapy/radiosurgery: QUIRO-DEGRO Trial. Strahlenther Onkol 188:769–776PubMedCrossRef
Metadaten
Titel
Protection of quality and innovation in radiation oncology
The prospective multicenter trial QUIRO of DEGRO: evaluation of time, attendance of medical staff, and resources during radiotherapy with tomotherapy
verfasst von
Dr. Cornelia Winkler
Dr. M. N. Duma
Dr. W. Popp
Prof. H. Sack
Prof. V. Budach
Prof. M. Molls
S. Kampfer
Publikationsdatum
01.10.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 10/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-014-0615-3

Weitere Artikel der Ausgabe 10/2014

Strahlentherapie und Onkologie 10/2014 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.